Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1544) 1544
science & technology (1163) 1163
life sciences & biomedicine (1119) 1119
piperacillin - therapeutic use (1036) 1036
male (917) 917
female (897) 897
penicillanic acid - analogs & derivatives (782) 782
anti-bacterial agents - therapeutic use (747) 747
middle aged (679) 679
penicillanic acid - therapeutic use (595) 595
adult (577) 577
piperacillin (562) 562
aged (537) 537
infectious diseases (483) 483
biological and medical sciences (456) 456
pharmacology & pharmacy (451) 451
medical sciences (449) 449
antibiotics (418) 418
microbiology (415) 415
tazobactam (379) 379
pharmacology. drug treatments (356) 356
microbial sensitivity tests (338) 338
piperacillin - administration & dosage (312) 312
antibiotics. antiinfectious agents. antiparasitic agents (299) 299
antibacterial agents (282) 282
adolescent (268) 268
treatment outcome (248) 248
bacterial infections - drug therapy (247) 247
piperacillin - pharmacology (240) 240
anti-bacterial agents - pharmacology (227) 227
anti-bacterial agents - administration & dosage (219) 219
aged, 80 and over (216) 216
prospective studies (215) 215
piperacillin - adverse effects (210) 210
drug therapy, combination (209) 209
drug therapy, combination - therapeutic use (187) 187
penicillanic acid - administration & dosage (187) 187
piperacillin-tazobactam (184) 184
penicillins - therapeutic use (180) 180
retrospective studies (175) 175
child (159) 159
drug resistance (158) 158
pseudomonas infections - drug therapy (154) 154
patients (152) 152
infections (151) 151
bacteria (150) 150
penicillanic acid - pharmacology (148) 148
piperacillin - pharmacokinetics (148) 148
pseudomonas aeruginosa - drug effects (147) 147
anti-bacterial agents - adverse effects (144) 144
hospitals (144) 144
penicillanic acid - adverse effects (144) 144
antimicrobial agents (142) 142
animals (138) 138
health aspects (136) 136
meropenem (135) 135
general & internal medicine (134) 134
risk factors (129) 129
cephalosporins - therapeutic use (125) 125
mortality (122) 122
pseudomonas aeruginosa (121) 121
abridged index medicus (119) 119
analysis (118) 118
polycyclic compounds (117) 117
anti-bacterial agents - pharmacokinetics (114) 114
piperacillin/tazobactam (114) 114
vancomycin (111) 111
child, preschool (107) 107
research (105) 105
bacteremia - drug therapy (102) 102
research article (102) 102
cross infection - drug therapy (101) 101
beta-lactamase inhibitors (99) 99
pneumonia (99) 99
surgery (99) 99
infant (97) 97
pathogens (97) 97
cefepime (96) 96
drug therapy (95) 95
escherichia coli - drug effects (93) 93
pediatrics (93) 93
drug resistance in microorganisms (92) 92
penicillanic acid - pharmacokinetics (92) 92
drug resistance, bacterial (90) 90
sepsis - drug therapy (90) 90
young adult (90) 90
ceftazidime (89) 89
pharmacokinetics (88) 88
e coli (87) 87
dosage and administration (86) 86
drug combinations (86) 86
sepsis (86) 86
oncology (85) 85
pharmacology (85) 85
medicine, general & internal (83) 83
infusions, intravenous (82) 82
internal medicine (82) 82
amikacin (81) 81
ciprofloxacin (80) 80
bacteria - drug effects (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1724) 1724
Japanese (64) 64
French (43) 43
Italian (33) 33
German (31) 31
Spanish (29) 29
Chinese (10) 10
Russian (10) 10
Portuguese (6) 6
Turkish (4) 4
Danish (2) 2
Dutch (2) 2
Hebrew (2) 2
Czech (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Polish (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
by Taccone, Fabio Silvio and Laterre, Pierre-François and Dugernier, Thierry and Spapen, Herbert and Delattre, Isabelle and Wittebole, Xavier and De Backer, Daniel and Layeux, Brice and Wallemacq, Pierre and Vincent, Jean-Louis and Jacobs, Frédérique
Critical care (London, England), ISSN 1364-8535, 07/2010, Volume 14, Issue 4, pp. R126 - R126
Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | beta-Lactams - pharmacokinetics | Anti-Bacterial Agents - blood | Ceftazidime - blood | Piperacillin - blood | Prospective Studies | Humans | Middle Aged | Male | Chromatography, High Pressure Liquid | Shock, Septic - metabolism | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Piperacillin - administration & dosage | beta-Lactams - blood | Anti-Bacterial Agents - therapeutic use | Sepsis - drug therapy | Sepsis - metabolism | Thienamycins - blood | Cephalosporins - blood | Shock, Septic - drug therapy | Penicillanic Acid - therapeutic use | Female | Drug Therapy, Combination | Penicillanic Acid - analogs & derivatives | Penicillanic Acid - administration & dosage | Thienamycins - therapeutic use | Anti-Bacterial Agents - pharmacokinetics | beta-Lactams - therapeutic use | Ceftazidime - therapeutic use | Penicillanic Acid - blood | Piperacillin - therapeutic use | Index Medicus | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pseudomonas skin infection: Clinical features, epidemiology, and management
by Wu, Douglas C and Chan, Wilson W and Metelitsa, Andrei I and Fiorillo, Loretta and Lin, Andrew N
American journal of clinical dermatology, ISSN 1175-0561, 2011, Volume 12, Issue 3, pp. 157 - 169
Research-and-development | Skin-infections, treatment | Amikacin | Meropenem, therapeutic use | Aminoglycosides | Cefepime, therapeutic use | Antibacterials, therapeutic use | Tobramycin, therapeutic use | Pseudomonal-infections, diagnosis | Pseudomonal-infections, treatment | Beta-lactams, therapeutic use | Folliculitis, treatment | Piperacillin, therapeutic use | Aztreonam, therapeutic use | Otitis-externa, treatment | Pseudomonal-infections, epidemiology | Ticarcillin, therapeutic use | Ceftazidime, therapeutic use | Ciprofloxacin, therapeutic use | Polymixins, therapeutic use | Bacteraemia, treatment | Fluoroquinolones, therapeutic use | Pseudomonal-infections, pathogenesis | Gentamicin, therapeutic use | Colistin, therapeutic use | Ceftobiprole, therapeutic use | Antibacterial-resistance | Imipenem, therapeutic use | therapeutic use | Life Sciences & Biomedicine | Dermatology | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | General aspects | Biological and medical sciences | Medical sciences | Epidemiology | Skin Diseases, Infectious - microbiology | Pseudomonas aeruginosa - isolation & purification | Pseudomonas Infections - epidemiology | Pseudomonas Infections - drug therapy | Humans | Drug Resistance, Bacterial | Skin Diseases, Infectious - drug therapy | Skin Diseases, Infectious - epidemiology | Anti-Bacterial Agents - pharmacology | Pseudomonas aeruginosa - drug effects | Pseudomonas Infections - microbiology | Pseudomonas aeruginosa infections | Care and treatment | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections
by Tamma, Pranita D and Rodriguez-Baňo, Jesus
Clinical infectious diseases, ISSN 1058-4838, 04/2017, Volume 64, Issue 7, pp. 972 - 980
ESBLs | Piperacillin-tazobactam | Cefepime | Carbapenems | Cephamycins | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Humans | Cephamycins - therapeutic use | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Piperacillin - pharmacology | beta-Lactamases - genetics | Penicillanic Acid - therapeutic use | beta-Lactamases - metabolism | Cephalosporins - pharmacology | Penicillanic Acid - analogs & derivatives | Penicillanic Acid - pharmacology | Piperacillin, Tazobactam Drug Combination | Enterobacteriaceae Infections - microbiology | Enterobacteriaceae - genetics | Treatment Outcome | beta-Lactamase Inhibitors - pharmacology | Cephamycins - pharmacology | beta-Lactamase Inhibitors - therapeutic use | Enterobacteriaceae - drug effects | Anti-Bacterial Agents - pharmacology | Enterobacteriaceae Infections - drug therapy | Piperacillin - therapeutic use | beta-Lactam Resistance - drug effects | Index Medicus | cefepime | carbapenems | piperacillin-tazobactam | Invited | cephamycins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii
by Yang, Ya-Sung and Lee, Yi and Tseng, Kuo-Chuan and Huang, Wei-Cheng and Chuang, Ming-Fen and Kuo, Shu-Chen and Lauderdale, Tsai-Ling Yang and Chen, Te-Li
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 07/2016, Volume 60, Issue 7, pp. 4047 - 4054
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Biofilms - drug effects | Imipenem - therapeutic use | Gentamicins - therapeutic use | Acinetobacter Infections - drug therapy | Pneumonia - microbiology | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Acinetobacter baumannii | Animals | Pneumonia - drug therapy | Minocycline - therapeutic use | Drug Resistance, Multiple, Bacterial | Taiwan | Penicillanic Acid - therapeutic use | Colistin - therapeutic use | Mice | Penicillanic Acid - analogs & derivatives | Piperacillin - therapeutic use | Thienamycins - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Treatment Options for Carbapenem-Resistant Gram-Negative Infections
by Fritzenwanker, Moritz and Imirzalioglu, Can and Herold, Susanne and Wagenlehner, Florian M and Zimmer, Klaus-Peter and Chakraborty, Trinad
Deutsches Ärzteblatt international, ISSN 1866-0452, 05/2018, Volume 115, Issue 20-21, pp. 345 - 352
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Klebsiella pneumoniae - drug effects | Ceftazidime - pharmacology | Escherichia coli - drug effects | Humans | Cephalosporins - standards | Piperacillin - standards | Cephalosporins - therapeutic use | Piperacillin - pharmacology | Carbapenems - pharmacology | Colistin - pharmacology | Pseudomonas aeruginosa - pathogenicity | Escherichia coli - pathogenicity | Fluoroquinolones - standards | Colistin - therapeutic use | Cephalosporins - pharmacology | Tigecycline - therapeutic use | Fosfomycin - therapeutic use | Fosfomycin - pharmacology | Fluoroquinolones - therapeutic use | Pseudomonas aeruginosa - drug effects | Carbapenems - standards | Gram-Negative Bacteria - drug effects | Drug Therapy, Combination - methods | Carbapenems - therapeutic use | Klebsiella pneumoniae - pathogenicity | Fluoroquinolones - pharmacology | Aminoglycosides - pharmacology | Carbapenem-Resistant Enterobacteriaceae - drug effects | Tigecycline - pharmacology | Ceftazidime - therapeutic use | Drug Therapy, Combination - standards | Germany | Aminoglycosides - therapeutic use | Piperacillin - therapeutic use | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Case-Control Study of Drug Monitoring of β-Lactams in Obese Critically Ill Patients
by Maya Hites and Fabio Silvio Taccone and Fleur Wolff and Frédéric Cotton and Marjorie Beumier and Daniel De Backer and Sandrine Roisin and Sophie Lorent and Rudy Surin and Lucie Seyler and Jean-Louis Vincent and Frédérique Jacobs
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2013, Volume 57, Issue 2, pp. 708 - 715
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Obesity | Biological and medical sciences | Metabolic diseases | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | beta-Lactams - pharmacokinetics | Anti-Bacterial Agents - blood | Ceftazidime - blood | Piperacillin - blood | Enzyme Inhibitors - blood | Humans | Middle Aged | Thienamycins - pharmacokinetics | Piperacillin - pharmacokinetics | Male | Drug Monitoring - methods | Case-Control Studies | Ceftazidime - pharmacokinetics | Cephalosporins - therapeutic use | Young Adult | beta-Lactams - blood | Anti-Bacterial Agents - therapeutic use | Sepsis - drug therapy | Thienamycins - blood | Cephalosporins - blood | Shock, Septic - drug therapy | Aged, 80 and over | Penicillanic Acid - therapeutic use | Adult | Cephalosporins - pharmacokinetics | Female | Penicillanic Acid - analogs & derivatives | Thienamycins - therapeutic use | Bacterial Infections - drug therapy | Renal Replacement Therapy | Enzyme Inhibitors - therapeutic use | Anti-Bacterial Agents - pharmacokinetics | Penicillanic Acid - pharmacokinetics | Aged | beta-Lactams - therapeutic use | Ceftazidime - therapeutic use | Penicillanic Acid - blood | Piperacillin - therapeutic use | Index Medicus | Clinical Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Effectiveness of patient choice in nonoperative vs surgical management of pediatric uncomplicated acute appendicitis
by Minneci, Peter C and Mahida, Justin B and Lodwick, Daniel L and Sulkowski, Jason P and Nacion, Kristine M and Cooper, Jennifer N and Ambeba, Erica J and Moss, R. Lawrence and Deans, Katherine J
JAMA surgery, ISSN 2168-6254, 05/2016, Volume 151, Issue 5, pp. 408 - 415
Life Sciences & Biomedicine | Surgery | Science & Technology | Appendicitis - complications | Appendectomy | Prospective Studies | Humans | Patient Participation | Male | Anti-Bacterial Agents - therapeutic use | Amoxicillin-Potassium Clavulanate Combination - therapeutic use | Appendicitis - economics | Metronidazole - therapeutic use | Penicillanic Acid - therapeutic use | Female | Child | Penicillanic Acid - analogs & derivatives | Appendicitis - drug therapy | Ciprofloxacin - therapeutic use | Treatment Outcome | Laparoscopy | Patient Preference | Health Care Costs | Adolescent | Appendicitis - surgery | Family | Anti-Bacterial Agents - administration & dosage | Piperacillin - therapeutic use
Journal Article
Details down arrow
8. Full Text Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis
by Scott T. Micek and Emily C. Welch and Junaid Khan and Mubashir Pervez and Joshua A. Doherty and Richard M. Reichley and Marin H. Kollef
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2010, Volume 54, Issue 5, pp. 1742 - 1748
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Infectious diseases | Bacterial diseases | Human bacterial diseases | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Bacterial sepsis | Antibiotics. Antiinfectious agents. Antiparasitic agents | Escherichia coli Infections - mortality | Multivariate Analysis | Humans | Middle Aged | Male | Acinetobacter Infections - mortality | Pseudomonas Infections - mortality | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Sepsis - drug therapy | Shock, Septic - drug therapy | Penicillanic Acid - therapeutic use | Adult | Female | Pseudomonas aeruginosa | Retrospective Studies | Drug Therapy, Combination | Penicillanic Acid - analogs & derivatives | Escherichia coli Infections - drug therapy | Hospital Mortality | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Fluoroquinolones - therapeutic use | Gram-Negative Bacterial Infections - drug therapy | Logistic Models | Shock, Septic - mortality | Sepsis - mortality | Carbapenems - therapeutic use | Aged | Aminoglycosides - therapeutic use | Cohort Studies | Gram-Negative Bacterial Infections - mortality | Piperacillin - therapeutic use | Index Medicus | Clinical Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016
by Sader, Helio S and Castanheira, Mariana and Duncan, Leonard R and Flamm, Robert K
Diagnostic microbiology and infectious disease, ISSN 0732-8893, 09/2018, Volume 92, Issue 1, pp. 69 - 74
Multidrug-resistant | carbapenem-resistant Enterobacteriaceae | Ceftazidime-avibactam | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Pseudomonas Infections - drug therapy | United States | Humans | Pseudomonas aeruginosa - drug effects | Cross Infection - drug therapy | Anti-Bacterial Agents - therapeutic use | Enterobacteriaceae - drug effects | Penicillanic Acid - therapeutic use | Azabicyclo Compounds - therapeutic use | Colistin - therapeutic use | Drug Resistance, Multiple, Bacterial - drug effects | Microbial Sensitivity Tests - methods | Ceftazidime - therapeutic use | Penicillanic Acid - analogs & derivatives | Enterobacteriaceae Infections - drug therapy | Piperacillin - therapeutic use | Thienamycins - therapeutic use | Levofloxacin | Pneumonia | Bacterial pneumonia | Aminoglycosides | Disease susceptibility | Medical centers | Pseudomonas aeruginosa | Urinary tract infections | Beta lactamases | Cross infection | Nosocomial infections | Health aspects | Ceftazidime | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship
by Cai, Tommaso and Verze, Paolo and Brugnolli, Anna and Tiscione, Daniele and Luciani, Lorenzo Giuseppe and Eccher, Cristina and Lanzafame, Paolo and Malossini, Gianni and Wagenlehner, Florian M.E and Mirone, Vincenzo and Bjerklund Johansen, Truls E and Pickard, Robert and Bartoletti, Riccardo
European urology, ISSN 0302-2838, 2015, Volume 69, Issue 2, pp. 276 - 283
Urology | Antimicrobial prophylaxis | Urinary tract infection | Cost saving | Surgical urology | Guidelines | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Escherichia coli - drug effects | Humans | Middle Aged | Drug Resistance, Bacterial | Male | Urologic Surgical Procedures - standards | Urology - standards | Anti-Bacterial Agents - therapeutic use | Aged, 80 and over | Penicillanic Acid - therapeutic use | Female | Penicillanic Acid - analogs & derivatives | Urologic Surgical Procedures - adverse effects | Anti-Bacterial Agents - economics | Gentamicins - therapeutic use | Piperacillin, Tazobactam Drug Combination | Ciprofloxacin - therapeutic use | Europe | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Antibiotic Prophylaxis - standards | Guideline Adherence | Klebsiella - drug effects | Aged | Piperacillin - therapeutic use | Practice Guidelines as Topic | Antibiotics | Associations, institutions, etc | Societies | Urinary tract infections | Medical care, Cost of | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights